Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
To assess if targeting activating EGFR and HER2 mutations in Non-Small Cell Lung Cancer
(NSCLC) is more effective when these mutations are truncal dominant mutations (≥50%), as
opposed to non-dominant (≥5 to <50%) or low frequency mutations (<5%).
This trial will be available to patients registered to the TRACERx study (NCT01888601), or
non-TRACERx patients who have two archival tissue/DNA samples who are willing to have a
biopsy of their relapsed disease.